181141-39-9 Usage
Description
Carbamic acid, (5-methyl-3-pyrrolidinyl)-, 1,1-dimethylethyl ester, (3S-cis)-, commonly known as sevelamer carbonate, is a chemical compound that serves as a phosphate binder. It is specifically utilized in the medical field for the treatment of hyperphosphatemia, a condition characterized by elevated levels of phosphate in the blood, often associated with chronic kidney disease. Sevelamer carbonate functions by binding to phosphate ions in the digestive tract, thereby preventing their absorption into the bloodstream and subsequently lowering overall phosphate levels in the body. This action is crucial in mitigating the risks of complications arising from kidney disease.
Uses
Used in Pharmaceutical Industry:
Sevelamer carbonate is used as a pharmaceutical agent for the management of hyperphosphatemia in patients with chronic kidney disease. It operates by binding to phosphate ions in the digestive system, which in turn reduces the absorption of these ions into the bloodstream, aiding in the control of phosphate levels and the prevention of related complications.
Used in Chronic Kidney Disease Management:
In the context of chronic kidney disease, sevelamer carbonate is employed as a critical component of therapy to address hyperphosphatemia. By managing phosphate levels, it helps in reducing the risk of complications associated with kidney disease, thus playing a significant role in the overall treatment strategy for patients with impaired kidney function.
It is typically administered orally and is available in tablet form or as a powder for suspension, allowing for flexibility in dosage and administration based on individual patient needs. Adherence to prescribed dosage and instructions is essential to ensure the therapeutic effectiveness of sevelamer carbonate and to minimize potential side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 181141-39-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,1,1,4 and 1 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 181141-39:
(8*1)+(7*8)+(6*1)+(5*1)+(4*4)+(3*1)+(2*3)+(1*9)=109
109 % 10 = 9
So 181141-39-9 is a valid CAS Registry Number.
181141-39-9Relevant articles and documents
COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
-
Page/Page column 87; 90, (2014/09/29)
Disclosed are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also disclosed are pharmaceutical compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.
COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
-
Page/Page column 91, (2014/09/29)
The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Quinolizinone type compounds
-
, (2008/06/13)
Antibacterial compounds having the formula STR1 and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds wherein A is =CR6 --; R1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R2 is selected from the group consisting of STR2 R3 is halogen; R4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR13 R14 ; and R6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.
